Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

Smart Beta ETF report for EUSA

Madeleine Johnson headshot

Why Novavax (NVAX) Stock Fell 19% on Friday

Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.

Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down

Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.

Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -26.33% and -19.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?

On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.

Sanghamitra Saha headshot

5 Best Inverse/Leveraged ETF Areas of Last Week

Wall Street was subdued last week. A slew of earnings results for the second quarter and a new report on consumer spending for June came in stronger than expected. But increasing cases of the delta variant of COVID-19 also weighed on risk-on sentiments.

Novavax (NVAX) Gains As Market Dips: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.

Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine

Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.

Kinjel Shah headshot

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed at $212.31 in the latest trading session, marking a +1.61% move from the prior day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $192.48, marking a +0.12% move from the previous day.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $192.24, marking a -1.1% move from the previous day.

Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

Mark Vickery headshot

Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More

The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.

Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.